Terms: = Leukemia AND CD52, CDW52, EDDM5 AND Prognosis
36 results:
1. cd52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract] [Full Text] [Related]
2. Subclones of bone marrow CD34
Jia R; Ji M; Li G; Xia Y; Guo S; Li P; Sun Y; Lu F; Zhang J; Zang S; Yan S; Ye J; Xue F; Ma D; Sun T; Ji C
Cancer; 2022 Nov; 128(22):3929-3942. PubMed ID: 36197314
[TBL] [Abstract] [Full Text] [Related]
3. [Comparison of the characteristics of NK cells after two different methods of expansion and observation of the clinical efficacy in patients who relapsed post allogeneic hematopoietic stem cell transplantation].
Cao XH; Wang ZD; Sun YQ; Kong J; Lu SY; Tang FF; Zhang YY; Wang JZ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ; Zhao XY
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):400-407. PubMed ID: 35680598
[No Abstract] [Full Text] [Related]
4. Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.
Wada M; Zhang H; Fang L; Feng J; Tse CO; Zhang W; Chen Q; Sha S; Cao Y; Chen KH; Pinz KG; Chen X; Fan XX; Jiang X; Ma Y
Stem Cell Rev Rep; 2020 Apr; 16(2):369-384. PubMed ID: 32008159
[TBL] [Abstract] [Full Text] [Related]
5. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract] [Full Text] [Related]
6. [Successful Treatment of T-Cell Prolymphocytic leukemia with Alemtuzumab].
Ueki D; Yoshida C; Tsutsumi Oota I; Seki M; Komeno T; Ito H; Ide Y
Gan To Kagaku Ryoho; 2019 May; 46(5):913-915. PubMed ID: 31189814
[TBL] [Abstract] [Full Text] [Related]
7. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract] [Full Text] [Related]
8. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract] [Full Text] [Related]
9. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract] [Full Text] [Related]
10. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
Le Jeune C; Thomas X
Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
[TBL] [Abstract] [Full Text] [Related]
11. cd52 is a molecular target in advanced systemic mastocytosis.
Hoermann G; Blatt K; Greiner G; Putz EM; Berger A; Herrmann H; Cerny-Reiterer S; Gleixner KV; Walz C; Hoetzenecker K; Müllauer L; Reiter A; Sotlar K; Sexl V; Valent P; Mayerhofer M
FASEB J; 2014 Aug; 28(8):3540-51. PubMed ID: 24760752
[TBL] [Abstract] [Full Text] [Related]
12. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract] [Full Text] [Related]
13. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.
Huang PY; Best OG; Almazi JG; Belov L; Davis ZA; Majid A; Dyer MJ; Pascovici D; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2014 Sep; 55(9):2085-92. PubMed ID: 24289109
[TBL] [Abstract] [Full Text] [Related]
14. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
[TBL] [Abstract] [Full Text] [Related]
15. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract] [Full Text] [Related]
16. Refractory chronic lymphocytic leukemia--new therapeutic strategies.
Schnaiter A; Stilgenbauer S
Oncotarget; 2010 Nov; 1(7):472-482. PubMed ID: 21317446
[TBL] [Abstract] [Full Text] [Related]
17. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
O'Brien S; Osterborg A
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):361-8. PubMed ID: 21030349
[TBL] [Abstract] [Full Text] [Related]
18. Chronic lymphocytic leukemia: insights from lymph nodes & bone marrow and clinical perspectives.
Jaksić O; Kardum-Skelin I; Jaksić B
Coll Antropol; 2010 Mar; 34(1):309-13. PubMed ID: 20432765
[TBL] [Abstract] [Full Text] [Related]
19. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.
Angiolillo AL; Yu AL; Reaman G; Ingle AM; Secola R; Adamson PC
Pediatr Blood Cancer; 2009 Dec; 53(6):978-83. PubMed ID: 19637330
[TBL] [Abstract] [Full Text] [Related]
20. Receptor-directed therapy of T-cell leukemias and lymphomas.
Morris JC; Waldmann TA; Janik JE
J Immunotoxicol; 2008 Apr; 5(2):235-48. PubMed ID: 18569395
[TBL] [Abstract] [Full Text] [Related]
[Next]
